ESC Professional Premium Access

Lipid-lowering by PCSK9 modulation: what’s new?

Event: ESC Congress 2022
Topic: Lipid-Lowering Agents
Session type: Abstract Sessions
Date: 26 August 2022
Time: 15:30 - 16:20

Congress Session

5 presentations in this session

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Speaker: Doctor D. Kannenkeril (Erlangen, DE)
Thumbnail

Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

Speaker: Doctor L. Raber (Bern, CH)
Thumbnail

Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data

Speaker: Professor M. Svensson (Uppsala, SE)
Thumbnail

Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

Speaker: Professor K. Ray (London, GB)
Thumbnail

High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"

Speaker: Professor O. Weingaertner (Jena, DE)
Thumbnail

5 speakers from this session

Doctor Dennis Kannenkeril

University Hospital Erlangen, Erlangen (Germany)
1 follower

Doctor Lorenz Raber

Swiss Cardiovascular Center, Bern (Switzerland)
8 presentations
0 follower

Professor Maria Svensson

Uppsala University and Uppsala University Hospital, Uppsala (Sweden)
0 follower

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
59 presentations
3 followers

Professor Oliver Weingaertner

University hospital Jena, Jena (Germany)
1 follower

This platform is supported by

logo Novo Nordisk